Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Novavax Covid-19 vaccine 93pc effective; offers total protection against 'moderate and severe' disease

Novavax’s Covid vaccine, NVX-CoV2373, has demonstrated 100 per cent protection against “moderate and severe disease”, the company said in a press release on Monday (June 14).

In the trial involving nearly 30,000 participants across 119 sites in the US and Mexico, the vaccine was found to be 93 per cent effective against variants that were circulating at the time of the trial – the alpha, beta and gamma variants that originated in the UK, South Africa and Brazil respectively, the company said, adding that the vaccine has 91 per cent efficacy in high-risk populations.


Preliminary safety data from the study also showed “generally mild and moderate” pain and tenderness around the injection site, as well as fatigue, muscle pain and headache were mentioned as the most common symptoms in participants.

Announcing the US trial results, Novavax said it will file for regulatory approval in the third quarter of the year and will be able to produce up to 100 million doses a month by then.

The UK has ordered 60 million doses of the Novavax vaccine, which has manufacturing agreements in Britain. Novavax has committed to provide 1.1bn doses to COVAX, the UN-led initiative to get vaccines to poorer countries.

Stanley C Erck, Novavax’s president and the chief executive officer said, “Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional Covid-19 vaccines.”

“These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe Covid-19 infection.”

The company said it will remain on track to reach a manufacturing capacity of 100m doses a month by the end of the third quarter and 150m doses a month by the end of 2021.

More For You

Air pollution in UK linked to thousands of deaths and chronic health conditions

A report by the Royal College of Physicians claims that air pollution was causing harm to almost every organ of the body.

iStock

Royal College of Physicians paints grim picture of air pollution in UK

Doctors warn that around 99 per cent of the population in the UK are breathing "toxic air", and around 30,000 deaths will be linked to air pollution in 2025.

The Royal College of Physicians (RCP) claimed in a report that air pollution was causing harm to almost every organ of the body, and shortening life by 1.8 years on average.

Keep ReadingShow less
Community pharmacies falling behind on data security toolkit submissions

The last date for submission is 30 June 2025.

Pic credit: iStock

Community pharmacies falling behind on data security toolkit submissions

More than 50 per cent of the community pharmacies in England have failed to complete their Data Security and Protection Toolkit 2025 with the deadline in less than two weeks.

Necessary guidance regarding the toolkit has previously been provided by Community Pharmacy England (CPE) earlier.

Keep ReadingShow less
Digital guide launched to help patients with osteoporosis

In the UK, over three million people have osteoporosis.

Pic credit: iStock

Digital guide launched to help patients with osteoporosis

The Royal Osteoporosis Society (ROS) has launched a free online service called BoneMed which is aimed to support patients with osteoporosis in taking their medicine and remove barriers to adherence.

After completing a five-minute online survey, patients will be emailed a summary of the medicine they have been prescribed and six further updates throughout the year on their medication.

Keep ReadingShow less
GPhC five-year plan to empower pharmacists, uphold public trust

GPhC's Strategic Plan 2025-30 will focus on empowering pharmacists and pharmacy technicians.

iStock

GPhC five-year plan to empower pharmacists, uphold public trust

The General Pharmaceutical Council (GPhC) launched its new plan for the next five years to uphold safety, quality and public trust in pharmacy.

The regulatory body unveiled its Strategic Plan 2025-30 during a Parliamentary event attended by pharmacy minister Stephen Kinnock on Wednesday (18).

Keep ReadingShow less
Glucose monitor and test strips on a blood sugar tracker sheet with lancets and pen device.

Medical device manufacturers will have to monitor the safety and performance of their products already in use.

iStock

Medical device regulation overhauled to improve patients' safety

Medical device manufacturers must now adhere to the UK's post-market surveillance (PMS) regulations.

The new rule came into effect on June 16, and manufacturers will have to monitor the safety and performance of their products already in use.

Keep ReadingShow less